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OBJECTIVE—A multicenter, controlled trial showed that early
blockade of the renin-angiotensin system in patients with type 1
diabetes and normoalbuminuria did not retard the progression of
nephropathy, suggesting that other mechanism(s) are involved in
the pathogenesis of early diabetic nephropathy (diabetic ne-
phropathy). We have previously demonstrated that endothelial-
mesenchymal-transition (EndoMT) contributes to the early
development of renal interstitial ﬁbrosis independently of mi-
croalbuminuria in mice with streptozotocin (STZ)-induced dia-
betes. In the present study, we hypothesized that blocking
EndoMT reduces the early development of diabetic nephropathy.
RESEARCH DESIGN AND METHODS—EndoMT was in-
duced in a mouse pancreatic microvascular endothelial cell line
(MMEC) in the presence of advanced glycation end products
(AGEs) and in the endothelial lineage–traceble mouse line Tie2-
Cre;Loxp-EGFP by administration of AGEs, with nonglycated
mouse albumin serving as a control. Phosphorylated Smad3 was
detected by immunoprecipitation/Western blotting and confocal
microscopy. Blocking studies using receptor for AGE siRNA and
a speciﬁc inhibitor of Smad3 (SIS3) were performed in MMECs
and in STZ-induced diabetic nephropathy in Tie2-Cre;Loxp-
EGFP mice.
RESULTS—Confocal microscopy and real-time PCR demon-
strated that AGEs induced EndoMT in MMECs and in Tie2-
Cre;Loxp-EGFP mice. Immunoprecipitation/Western blotting
showed that Smad3 was activated by AGEs but was inhibited by
SIS3 in MMECs and in STZ-induced diabetic nephropathy. Con-
focal microscopy and real-time PCR further demonstrated that
SIS3 abrogated EndoMT, reduced renal ﬁbrosis, and retarded
progression of nephropathy.
CONCLUSIONS—EndoMT is a novel pathway leading to early
development of diabetic nephropathy. Blockade of EndoMT
by SIS3 may provide a new strategy to retard the progression
of diabetic nephropathy and other diabetes complications.
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D
iabetic nephropathy is a major microvascular
complication of both type 1 and type 2 diabetes.
Increased glomerular basement membrane
thickness, mesangial expansion, glomerular
sclerosis, and tubulointerstitial ﬁbrosis are major features
of diabetic nephropathy. The severity of glomerulosclero-
sis and tubulointerstitial ﬁbrosis are strong predictors of
the progression to end-stage renal disease, making this an
important therapeutic target.
Current clinical treatment guidelines for diabetic ne-
phropathy include the control of hyperﬁltration, mi-
croalbuminuria, systemic blood pressure, and blood
glucose (1). Multiple clinical trials have shown that block-
ade of the renin-angiotensin system (RAS) can improve
renal function in late diabetic nephropathy in patients with
proteinuria, diabetes, and reduced glomerular ﬁltration
rate (2–4). Recently, however, a large-scale multicenter
controlled trial revealed that inhibition of the RAS in
normotensive patients with type 1 diabetes and nor-
moalbuminuria did not reduce the incidence of microalbu-
minuria or slow the decline of renal function, suggesting
that the pathogenesis of early diabetic nephropathy may
differ from that of late diabetic renal disease (5).
Myoﬁbroblasts are major contributors to extracellular
matrix (ECM) accumulation in ﬁbrotic disease, and their
numbers inversely correlate with renal function in diabetic
nephropathy (6,7). It is generally believed that myoﬁbro-
blasts can be derived from renal ﬁbroblasts, tubular epi-
thelial cells, mesangial cells, and bone marrow–derived
cells. Recently, Zeisberg et al. (8) showed that endothelial-
mesenchymal-transition (EndoMT) contributed to cardiac
ﬁbrosis. They further demonstrated that 30–50% of ﬁbro-
blasts in three different mouse models of renal disease
(unilateral ureteral obstructive [UUO] nephropathy, strep-
tozotocin [STZ]-induced diabetic nephropathy, and a
mouse model of Alport syndrome) coexpressed the endo-
thelial marker CD31 and the ﬁbroblast/myoﬁbroblast
markers ﬁbroblast speciﬁc protein-1 and/or -smooth mus-
cle actin (-SMA) (9) . We also recently demonstrated that
10–24% of renal interstitial myoﬁbroblasts in 1- and
6-month STZ-induced diabetic kidneys were of endothelial
origin, revealing the existence of EndoMT in the develop-
ment and progression of diabetic nephropathy (10). How-
ever, it is unclear whether blockade of EndoMT can
reduce renal ﬁbrosis and retard the early development of
diabetic nephropathy.
There is increasing evidence of a causal role for ad-
vanced glycation end products (AGEs) in the development
of diabetes complications, including nephropathy and vas-
culopathy (11,12). AGEs exert their effects through the
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and function of ECM and by interacting with speciﬁc cell
surface receptors (11). The best-characterized AGE
receptor is receptor for AGEs (RAGE), although other
AGE-binding sites have been identiﬁed (12). Disruption
of the RAGE gene ameliorates development and pro-
gression of diabetic nephropathy (13). AGEs have also
been shown to cause epithelial-mesenchymal transdif-
ferentiation via RAGE in diabetic nephropathy (14). It is
unknown whether AGEs can induce EndoMT and, if
they can, whether blockade of AGE-induced EndoMT
can ameliorate the development and progression of
diabetic renal ﬁbrosis.
The interaction of AGEs and RAGE on endothelial cells
induces cellular oxidant stress and initializes serial signal-
ing pathway activation, including the nuclear factor-B,
extracellular signal–regulated kinase 1 and 2 (ERK1/2),
p38 mitogen-activated protein kinase (MAPK), stress-acti-
vated protein kinase/c-Jun–NH2-terminal kinase (SAPK/
JNK) and the small GTPase Ras, -family small GTPase
Cdc42, and Rac1 pathways (15–23). AGEs also induce
rapid and transient activation of Smad2 and Smad3 in
tubular epithelial cells, mesangial cells, and vascular
smooth muscle cells through RAGE-Smad2/3 cross-talk
(24). Whether AGEs can induce Smad3 activation in renal
endothelial cells and whether blockade of RAGE-Smad3
cross-talk abrogates AGE-induced EndoMT requires fur-
ther investigation.
Smad3 plays an essential role in renal ﬁbrosis. Smad3
conditional knockout mice have been shown to be resis-
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FIG. 1. AGEs induced EndoMT in MMECs. MMECs were cultured in the presence of AGEs (25 g/ml) or BSA (25 g/ml) for 3 and 7 days (3d AGEs,
7d BSA, and 7d AGEs). Confocal microscopy demonstrated the expression of VE-cadherin (green), -SMA (red), and DAPI nuclear staining (blue)
in MMECs after culture with either BSA (A) or AGEs (B) for 7 days. Arrow indicates a VE-cadherin
/-SMA
 cell. C: Quantitation of the
percentages of VE-cadherin– and -SMA–positive cells in total DAPI-positive cells. One-way ANOVA, a, vs. 7d BSA, b (P < 0.05) b, vs. 3d AGEs
(P < 0.05). Real-time PCR demonstrated mRNA levels of -SMA (D and F) and CD31 (E and G) in MMECs cultured in the presence of BSA or
AGEs for 3, 6, and 24 h (D and E) and with different concentrations of AGEs and BSA for 24 h (F and G). D: Two-way ANOVA, time, P < 0.05;
treatment, P < 0.05; interaction, P < 0.05. E: Two-way ANOVA, time, P > 0.05; treatment, P < 0.05; interaction, P < 0.05. F: c, vs. 25 g/ml BSA
or 1 g/ml AGEs, P < 0.05; d, vs. 5 g/ml AGEs, P < 0.05. G: e, vs. 25 g/ml BSA or 1 g/ml AGEs, P < 0.05; f, vs. 5 g/ml AGEs, P < 0.05. (A
high-quality digital representation of this ﬁgure is available in the online issue.)
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ﬁbrosis in UUO models (25–27). Recently, Jinnin et al. (28)
showed that a speciﬁc inhibitor of Smad3 (SIS3) inhibited
Smad3 phosphorylation and reduced a transforming
growth factor (TGF)-1–induced ﬁbrotic response in ﬁbro-
blasts (10). We also demonstrated that SIS3 can abolish
TGF-1–induced EndoMT in mouse pancreatic microvas-
cular endothelial cells (MMECs) (10). Whether SIS3 can
inhibit AGE-induced EndoMT in vitro and in vivo remains
to be explored.
In the present study, we hypothesized that AGEs can
induce EndoMT and that blockade of RAGE-Smad3 cross-
talk not only abrogates AGE-induced EndoMT but also
retards the early development of renal ﬁbrosis in STZ-
induced diabetic mice. AGE-induced EndoMT was exam-
ined in MMECs and in an endothelial lineage–traceble
mouse line (Tie2-Cre;Loxp-EGFP) while the efﬁcacy of
SIS3 was tested in AGE-induced EndoMT in MMECs and in
mice with STZ-induced diabetes.
RESEARCH DESIGN AND METHODS
B6.Cg-Tg(Tek-cre)12F1v/J mice (stock no. 004128) and B6.Cg-Tg(ACTB-
Bgeo/GFP)21Lbe/J mice (stock no. 004178) were purchased from the The
Jackson Laboratories (Bar Harbor, ME). Male C57BL/6J mice (20–25g) were
obtained from Monash Animal Services, Monash University, Australia. -SMA/
EYFP (enhanced yellow ﬂuorescent protein) mice were kindly provided by Dr.
James Lessard (Cincinnati Children’s Hospital Medical Centre, Cincinnati,
OH). In -SMA/EYFP mice, EYFP expression is driven by the -SMA promot-
er/enhancer and is expressed not only in smooth muscle cells but also in renal
myoﬁbroblasts. The isolation and culture of mouse renal CD31
/EYFP
 cells
has previously been described (10). All animal experiments were performed
with the approval of a Monash University Animal Ethics Committee and
adhered to the Australian Code of Practice for the Care and Use of Animals
for Scientiﬁc Purposes.
The generation of RAGE-null mice and induction of diabetes in RAGE-null
and wild-type mice were described previously (13). Kidneys from 16- and
32-week-old diabetic and nondiabetic mice were used for periodic acid-Schiff
(PAS) staining and confocal microscopy analysis.
Tie2-Cre;Loxp-EGFP mice were generated by cross-breeding B6.Cg-
Tg(Tek-cre)12F1v/J mice with B6.Cg-Tg(ACTB-Bgeo/GFP)21Lbe/J mice. For
the time course study, diabetes was induced in Tie2-Cre;Loxp-EGFP mice
(n  12) at 8 weeks of age by intraperitoneal administration of 50 g/g STZ
(Sigma-Aldrich, St. Louis, MO) for ﬁve consecutive days. Control Tie2-Cre;
Loxp-EGFP mice (n  6) received daily intraperitoneal injections of normal
saline for 5 days. Mice were killed 1 and 3 month(s) after the onset of diabetes.
Blood, urine, and kidney tissue were analyzed for biochemical parameters and
renal histology. Urine in the bladder was collected for urinary albumin
excretion once the mice were killed. The albumin-to-creatinine ratio was
measured with Albuwell M and Creatinine Companion (Exocell, Philadel-
phia, PA).
A preliminary experiment was performed to determine the effective dose
range of SIS3 in STZ-induced diabetic kidney disease. Diabetes was induced in
male C57BL/6J mice by intraperitoneal injection of STZ as described above.
One month after the onset of diabetes, mice were divided into four groups
(n  3) and given two intraperitoneal injections of 1, 2.5, or 5 g/g body
weight SIS3 or vehicle with a 5-h interval and then killed 1 h after the second
injection for examination of the levels of renal Smad2 and Smad3 phosphor-
ylation. Immunoprecipitation and western Blotting demonstrated that 2.5 g/g
SIS3 was sufﬁcient to achieve more than 90% inhibition of phosphorylation of
Smad3, compared with the vehicle-treated group, without obvious side effects.
Therefore, in the main study, to test the beneﬁcial role of SIS3, 4 weeks after
onset of diabetes mice were treated with the same volume of vehicle or
2.5 mg  kg
1  day
1 SIS3 delivered by implantation of an Alzet (Durect Corp.,
Cupertino, CA) osmotic pump for 8 weeks. By the experimental end point,
mice were killed and blood, urine, and kidney tissue were collected for
analysis.
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FIG. 2. Infusion of AGEs into Tie2-Cre;Loxp-EGFP mice induced EndoMT.
Confocal microscopy demonstrated EGFP (green), -SMA (red), and DAPI
(blue) staining in MSA-treated (A) and AGEs-treated (B) mouse kidneys.
Arrow indicates EGFP
/-SMA
 cells in an AGEs-treated kidney (seen at
higher magniﬁcation in C–E). Arrow heads indicate EGFP
/-SMA
 cells in
an AGEs-treated kidney (seen at higher magniﬁcation in F–H. Original
magniﬁcation: A and B, 600; C and H, 1,200. I: Quantiﬁcation of
percentage of -SMA
/EGFP
 cells in total -SMA
 cells in MSA-treated
and AGEs-treated kidneys. a, vs. MSA-treated group, P < 0.05. (A high-
quality digital representation of this ﬁgure is available in the online issue.)
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1  day
1;
Sigma) or mouse serum albumin (MSA) (10 g  g
1  day
1; Sigma) was
administered into male Tie2-Cre;Loxp-EGFP mice (n  3) for 1 month by
osmotic micropumps. To test whether SIS3 can block EndoMT in vivo, MSA
(10 g  g
1  day
1), AGEs (10 g  g
1  day
1) plus vehicle, or AGEs (10 g
 g
1  day
1) plus SIS3 (2.5 mg  kg
1  day
1) were administered into male
Tie2-Cre;Loxp-EGFP mice (n  3) for 1 month by separate osmotic mi-
cropumps. By the experimental end point, mice were killed and kidney tissues
were collected for analysis.
Histology and confocal microscopy. The following antibodies were used for
immunoﬂuorescence studies: rat anti-CD31(BD Biosciences, San Diego, CA),
rabbit anti–Von Willebrand factor (vWF) (Dako, Glostrup, Denmark), mouse
anti–-SMA conjugated with cyanine three (Sigma-Aldrich), rat anti–VE-
cadherin (eBioscience, San Diego, CA), rabbit anti–phosphorylated Smad3
(Novus Biologicals, Littleton, CO), rabbit anti-ﬁbronectin (Sigma-Aldrich),
goat anti–collagen IV, goat anti–rabbit Alexa Fluor 555 conjugate, goat
anti–rat Alexa Fluor 647 conjugate, and chicken anti–goat 647 conjugate
(Invitrogen). Goat anti-RAGE neutralizing antibody and mouse anti–TGF-1
neutralizing antibody (R&D Systems) were also used. Sections were counter-
stained with DAP) to visualize nuclei. Sections were analyzed with an
Olympus Fluoview 1000 confocal microscope (Olympus, Tokyo), FV10-ASW
software (version 1.7; Olympus), and oil Uplan ﬁlter 60	 objective (NA 1.25;
Olympus) at 2	,3 	,o r6 	 digital zoom. Channels were acquired sequentially.
Contrast and brightness of the images were further adjusted using Image J
(rsbweb.nih.gov/ij). The degree of tubulointerstitial ﬁbrosis was measured in
40 randomly selected high-power ﬁelds (	600) in each animal using Image J
software by analyzing the percentage of the total cortical area accounted for
by immunostaining for -SMA, collagen IV, or ﬁbronectin. All scoring was
performed blind on coded slides.
Quantitation of myoﬁbroblasts of endothelial cell origin. Enhanced
green ﬂuorescent protein (EGFP)
/-SMA
 cells were counted in renal
cortex. Five cortical ﬁelds were analyzed at 600	 magniﬁcation in each of ﬁve
sections from each kidney. The number of endothelial cell–origin myoﬁbro-
blasts per millimeter squared of cortex (excluding glomeruli) (EGFP
/-
SMA
 cells/millimeter squared of cortex) was determined, as was the
percentage of -SMA
/EGFP
 cells in total -SMA
 cells.
MMEC culture. MMECs were cultured as previously described (9). AGEs
(Sigma-Aldrich) were added at concentrations of 1, 5, and 25 g/ml to the cell
cultures for 3 and 7 days in chamber slides and 3, 6, and 24 h in 6-well plates,
with 25 g/ml BSA used as the control. In blocking studies, MMECs were
pretreated with goat anti-RAGE neutralizing antibody (4 g/ml), mouse
anti–TGF-1 neutralizing antibody (4 g/ml), normal goat immunoglobulin G
(IgG) (4 g/ml), normal mouse IgG (4 g/ml), and SIS3 (2 mol/l; Sigma
Aldrich) or vehicle (DMSO) for 30 min; then, AGEs were added for different
periods of time as described above. The treated cells were subsequently
subjected to immunoprecipitation/Western blotting and real-time PCR.
RAGE, TGF- receptor 1, Smad2, and Smad3 knockdown. Control siRNA
(category no. 12935-200), RAGE siRNA (category no. MSS218607), TGF-
receptor 1 siRNA (category no. RSS355451), Smad2 siRNA (category no.
MSS206406), and Smad3 siRNA (category no. MSS206422) were purchase
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FIG. 3. AGE-induced EndoMT was RAGE-mediated in MMECs. Confocal microscopy demonstrated the expression of RAGE (green), CD31 (red),
and DAPI (blue) in kidney 1 month after administration of either normal saline (A) or STZ (B). Original magniﬁcation for A and B, 600. C:
Mouse renal endothelial cells were treated with control siRNA (CTL siRNA) and RAGE siRNA for 24 h and then stimulated with BSA or AGEs
for 48 h. Western blotting demonstrated the expression of RAGE, VE-cadherin (VE-cad), -SMA, and GAPDH. D and E: Real-time PCR
demonstrated mRNA levels of -SMA (D) and CD31 (E) in MMECs after culture with BSA, AGEs, AGEs plus goat anti-RAGE neutralizing
antibody or AGEs plus goat IgG for 24 h. a, vs. BSA, P < 0.05; b, vs. AGEs and AGEs plus goat IgG, respectively, P < 0.05. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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MMECs were transfected in triplicate with RAGE siRNA, TGF- receptor 1
siRNA, Smad2 siRNA, and Smad3 siRNA or control siRNA using lipofectamine
2000. Twenty-four hours following transfection, the transfected cells were
subjected to BSA or AGEs stimulation for 30 mins, 24 h, or 48 h. Cells were
harvested for immunoblotting or real-time PCR analysis.
RNA extraction and real-time PCR. Total RNA from kidneys or MMECs
was isolated, and RT-PCR and real-time PCR were performed with an RT-PCR
kit (Invitrogen) and SYBR Green PCR Reagents (Sigma). Primers were as
follows: mouse CD31, 5
-aggcttgcatagagctccag and 5
-ttcttggtttccagctatgg;
-SMA, 5
-ctgacagaggcaccactgaa and 5
-gaaatagccaagctcag; mouse collagen
IV, 5
aaagggagaaagaggcttgc and 5
 ctccctttgtaccgttgcat; mouse ﬁbronectin,
5
gaagcaacgtgctatgacga and 5
atctagcggcatgaagcact; and mouse glyceralde-
hyde 3 phosphate dehydrogenase (GAPDH), 5
-cagatccacaacggatatattggg and
5
-catgacaactttggcattgtgg. Reaction speciﬁcity was conﬁrmed by electro-
phoretic analysis of products before real-time PCR, and bands of expected
size were detected. Ratios of CD31 to GAPDH, -SMA to GAPDH, collagen IV
to GAPDH, and ﬁbronectin to GAPDH were calculated for each sample and
expressed as means  SD. The relative amounts of mRNA were calculated
using the comparative Ct (Ct) method compared with GAPDH and are
expressed as means  SD.
Immunoprecipitation and Western blotting. Kidney and cell culture
samples were sonicated and resuspended in 0.4 ml RIPA lysis buffer. Protein
concentration estimations were performed with a detergent-compatible pro-
tein assay kit (Bio-Rad, Hercules, CA). Samples containing 500 g total protein
were immunoprecipitated with a rabbit anti-Smad3 antibody (Cell Signaling
Technology, Danvers, MA) followed by Western blotting with mouse anti-
phosphoserine (Calbiochem, Kilsyth, Victoria, Australia) or mouse anti-Smad3
(Santa Cruz Biotechnology, Santa Cruz, CA). Blots were then incubated with
peroxidase-conjugated goat anti–rabbit IgG, goat anti–mouse IgG, or goat
anti–mouse IgM (Sigma-Aldrich), and bound antibody was detected by ECL
Plus (Amersham, Little Chalfont, U.K.) and captured by Fujiﬁlm model
LAS-3000 (Fujiﬁlm Corporation). Densitometry analysis was performed with a
Gel Pro analyzer (Media Cybernetics, Silver Spring, MD).
Statistical analysis. Data are presented as means  SD, with statistical
analyses performed using one-way ANOVA from GraphPad Prism 5.0 or
two-way ANOVA if appropriate (GraphPad Software, San Diego, CA). Post-
test Tukey’s analysis was used when appropriate. A P value 
0.05 was
considered statistically signiﬁcant.
RESULTS
AGEs induced EndoMT in MMECs and in Tie2-Cre;
Loxp-EGFP mice. To investigate whether AGEs can
induce EndoMT, we cultured MMECs in the presence of
AGEs and unglycated BSA. MMECs have previously been
shown to transdifferentiate into myoﬁbroblasts in vitro
upon TGF-1 stimulation (10). Confocal microscopy (Fig.
1A–C) and real-time PCR (Fig. 1D–G) demonstrated that
AGEs, but not BSA, induced de novo expression of -SMA,
a putative marker of myoﬁbroblasts. Concurrently, MMEC
expression of the endothelial cell markers VE-cadherin
(protein) and CD31 (mRNA) were lost in a time- and
dose-dependent fashion. To corroborate the ﬁndings in
vivo, AGEs or MSA were administrated to Tie2-Cre;Loxp-
EGFP mice by osmotic micropumps. In Tie2-Cre;Loxp-
EGFP mice, expression of EGFP in renal endothelial cells
persists despite subsequent phenotypic changes (10). Con-
focal microscopy demonstrated that by 1 month after
AGEs infusion, EGFP
/-SMA
 cells were present in the
renal interstitium but were not present in mice adminis-
tered MSA (AGEs vs. MSA 5.4  1.4 vs. 0.1  0.3%; P 

0.05) (Fig. 2A–I). Thus, both in vitro and in vivo studies
demonstrated the existence of AGE-induced EndoMT in
microvascular endothelial cells.
RAGE-Smad3 cross-talk mediated AGE-induced
EndoMT in MMECs. To investigate the expression of
RAGE in renal endothelial cells, anti-RAGE and anti-CD31
antibodies were employed. Confocal microscopy demon-
strated that the expression of RAGE was signiﬁcantly
increased in 1-month STZ-induced diabetic kidneys com-
pared with normal saline-treated mouse kidneys (Fig. 3A
and B). The colocalized expression of RAGE with CD31
demonstrated the signiﬁcant upregulation of RAGE ex-
pression in diabetic renal endothelial cells both in glomer-
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/ (K) kidneys. Original magniﬁcation: A–D, 400; E–G and K, 600; and H–J, 1800. Quantiﬁcation of number of -SMA
 renal
interstitial myoﬁbroblasts (L) and percentage of vWF
/-SMA
 cells in total -SMA
 cells (M). a, vs. nondiabetic kidneys, P < 0.05; b, vs. diabetic
RAGE
/ kidneys, P < 0.05. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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investigate whether AGE-induced EndoMT involves signal-
ing through RAGE, RAGE siRNA was employed. Western
blotting demonstrated that knockdown of RAGE abolished
AGE-induced loss of VE-cadherin and de novo expression
of -SMA in mouse endothelial cells (Fig. 3C). MMECs
were also preincubated with goat anti-RAGE neutralizing
antibody or goat IgG. Real-time PCR demonstrated that
pretreatment with the anti-RAGE neutralizing antibody,
but not control goat IgG, reduced AGE-induced -SMA
mRNA expression by 64% and inhibited loss of CD31 by
60% compared with AGEs treatment alone and cotreat-
ment with AGEs and goat IgG (Fig. 3D and E). To further
corroborate RAGE-mediated EndoMT in diabetes, diabe-
tes was induced in RAGE-null and wild-type mice. PAS
staining demonstrated that renal ﬁbrosis was signiﬁcantly
reduced in RAGE-null diabetic kidney compared with
RAGE–wild-type diabetic kidney (Fig. 4A–D). More impor-
tantly, confocal microscopy showed that the number of
-SMA
 renal myoﬁbroblasts and the percentage of vWF
/
-SMA
 cells in total -SMA
 cells were signiﬁcantly
lower in RAGE-null mouse kidney than in RAGE–wild type
mouse kidney (Fig. 4E–M). This suggests that AGE-in-
duced EndoMT occurs largely through RAGE. Next, we
investigated whether AGEs can induce Smad3 activation
and whether AGE-induced Smad3 activation occurs
through RAGE. Immunoprecipitation/Western blotting
demonstrated that incubation with AGEs induced Smad3
activation in a time- and dose-dependent fashion in
MMECs (Fig. 5A and B). This AGE-induced Smad3 activa-
tion was reduced by 65% when MMECs were cultured in
the presence of the anti-RAGE neutralizing antibody (Fig.
5D). When RAGE siRNA was employed in MMECs, this
AGE-induced rapid Smad3 phosphorylation was almost
abrogated (Fig. 5C). To further conﬁrm RAGE-Smad3
cross-talk induced by AGEs, an anti–TGF-1 neutralizing
antibody and TGF- receptor 1 siRNA were employed in
MMECs. Western blotting demonstrated that the anti–
TGF-1 neutralizing antibody could block TGF-1–in-
duced but not AGE-induced rapid Smad3 activation (30
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knockdown of TGF- receptor 1 abrogated TGF-1–in-
duced but not AGE-induced rapid Smad3 activation (30
min) in MMECs (Fig. 5F). Thus, the experiment results
demonstrate that RAGE-Smad3 cross-talk is a major path-
way mediating AGE-induced Smad3 activation in MMECs.
SIS3 abrogated AGE-induced Smad3 activation and
EndoMT in MMECs. SIS3 has previously been shown to
inhibit Smad3 phosphorylation in ﬁbroblasts (28), and we
reported that SIS3 abolished TGF-1–induced EndoMT in
MMECs (10). To investigate whether SIS3 can block
AGE-induced activation of Smad3, MMECs were pre-
treated with 1 mol/l SIS3 for 30 mins. Immunoprecipita-
tion/Western blotting demonstrated that SIS3 abolished
AGE-induced phosphorylation of Smad3 but not Smad2,
suggesting the speciﬁcity of SIS3 in vitro (Fig. 6A). Next,
we investigated whether SIS3 could inhibit AGE-induced
EndoMT in MMECs. Confocal microscopy demonstrated
that pretreatment with SIS3 not only blocked AGE-in-
duced de novo expression of -SMA but also inhibited
AGE-induced loss of VE-cadherin in MMECs (Fig. 6B–E),
indicating the efﬁcacy of SIS3 in inhibition of AGE-induced
Smad3 phosphorylation and EndoMT in MMECs. To fur-
ther differentiate the role of Smad2 and Smad3 in AGE-
induced EndoMT, Smad2 siRNA and Smad3 siRNA were
employed. Western blotting demonstrated that Smad2
siRNA and Smad3 siRNA signiﬁcantly knocked down
endogenous Smad2 and Smad3, respectively, in MMECs
(Fig. 6F). Real-time PCR demonstrated that knockdown of
Smad3 but not Smad2 almost abolished AGE-induced de
novo expression of -SMA in MMECs (Fig. 6G), suggesting
the pivotal role of Smad3 in AGE-induced EndoMT.
SIS3 inhibited Smad3 activation in STZ-induced
diabetic nephropathy in Tie2-Cre;Loxp-EGFP mice.
Analysis of STZ-induced diabetic kidneys by immunopre-
cipitation/Western blotting identiﬁed substantial Smad3
phosphorylation 1 month after induction of diabetes. Lev-
els of Smad3 phosphorylation remained elevated 3 months
after STZ administration (Fig. 7A). Under a regime of
multiple low-dose STZ injections, 80% of the animals
developed diabetes (29). Immunoprecipitation/Western
blotting demonstrated that the level of Smad3 phosphory-
lation was not increased in STZ-injected nondiabetic
mouse kidney compared with normal saline-injected and
STZ-injected diabetic mouse kidneys (Fig. 7B), suggesting
that the elevated Smad3 phosphorylation is associated
with diabetes—not STZ. Confocal microscopy further con-
ﬁrmed a signiﬁcant increase in levels of phosphorylated
Smad3 in renal endothelial cells of diabetic mice com-
pared with normal saline-injected mice (Fig. 7E–I). One
month after the onset of STZ-induced diabetes, mice were
given intraperitoneal injection of vehicle and different
dosages of SIS3. Immunoprecipitation/Western blotting
demonstrated that SIS3 blocked Smad3 but not Smad2
activation in STZ-induced diabetic mouse kidneys, sug-
gesting the speciﬁcity of SIS3 in vivo (Fig. 7C). To explore
whether SIS3 can inhibit Smad3 activation in STZ-induced
diabetic nephropathy, SIS3 (2.5 g  g
1  day
1) or the
same volume of vehicle was administered to Tie2-Cre;
Loxp-EGFP mice by osmotic micropumps for 2 months
commencing 1 month after the administration of STZ.
ImmunoprecipitationP/Western blotting demonstrated
that after 2 months of SIS3 administration, Smad3 activa-
tion in STZ diabetic mice was almost abolished compared
with high levels of Smad3 activation in kidneys of vehicle-
injected mice (Fig. 7D). Confocal microscopy demon-
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FIG. 7. SIS3 inhibited Smad3 activation in STZ-induced diabetic ne-
phropathy. Immunoprecipitation/Western blotting demonstrated the
time course of phosphorylated Smad3 (p-Smad3) and total levels of
Smad3 in STZ-induced diabetic mouse kidneys and normal saline
(NS)-treated kidneys (A) and p-Smad3 and total Smad3 in normal
saline-treated, STZ-injected nondiabetic (STZ/DM) and STZ-in-
jected diabetic (STZ/DM) mouse kidneys (B). C: One month after
the onset of STZ-induced diabetes or normal saline treatment, diabetic
mice were given intraperitoneal injection of vehicle and different
dosages of SIS3. Immunoprecipitation/Western blotting demonstrated
p-Smad3, total Smad3, p-Smad2, and total Smad2 in kidneys of mice
with different treatments. D: Immunoprecipitation/Western blotting
demonstrated p-Smad3 and total Smad3 in normal saline-treated
mouse kidneys, STZ-induced diabetic nephropathy plus vehicle-treated
mouse kidneys, and STZ-induced diabetic nephropathy plus SIS3-
treated (2.5 g  g
1  day
1) mouse kidneys. Confocal microscopy
demonstrated CD31 (green), p-Smad3 (red), and DAPI (blue) staining
in 1-month normal saline-treated kidney (E), 1-month STZ-induced
diabetic kidney (F), 3-month STZ-induced diabetic nephropathy plus
vehicle-treated mouse kidney (H), and 3-month STZ-induced diabetic
nephropathy plus SIS3-treated mouse kidney (I). G: Quantitation of
percentage of phosporylated Smad3–positive cells in total CD31-posi-
tive cells in 1-month normal saline-treated and STZ-injected diabetic
kidneys. J: Quantitation of percentage of phosphorylated Smad3–
positive cells in total CD31-positive cells in 3-month normal saline-
treated and STZ-induced diabetic nephropathy plus vehicle-treated
and STZ-induced diabetic nephropathy plus SIS3 treated kidneys. a, vs.
normal saline, P < 0.05; b, vs. STZ-induced diabetic nephropathy plus
vehicle-treated kidneys, P < 0.05. Original magniﬁcation: C, D, F, and
G, 600. (A high-quality digital representation of this ﬁgure is avail-
able in the online issue.)
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STZ diabetic mice was inhibited by SIS3 (Fig. 7H–J),
indicating the efﬁcacy of SIS3 in vivo.
SIS3 reduced AGE-induced EndoMT and decreased
EndoMT in STZ-induced diabetic nephropathy in
Tie2-Cre;Loxp-EGFP mice. To investigate the effect of
SIS3 on AGE-induced EndoMT in vivo, MSA, AGEs plus
vehicle and AGEs plus SIS3 were administered into Tie2-
Cre;Loxp-EGFP mice by osmotic pumps for 1 month.
Confocal microscopy demonstrated that compared with
vehicle treatment, SIS3 signiﬁcantly inhibited AGE-in-
duced EndoMT in Tie2-Cre;Loxp-EGFP mouse kidneys
(Fig. 8A–H). Next, we examined the effects of SIS3 on
EndoMT in STZ-induced diabetic nephropathy in Tie2-
Cre;Loxp-EGFP mice. Confocal microscopy demon-
strated that SIS3 reduced the percentage of EGFP
/-
SMA
 cells in total -SMA
 cells and the total number
of -SMA
 cells in the renal interstitium compared with
the vehicle-injected group (2.7  0.8 vs. 14.2  4.0% and
30.3  10.5 vs. 158.7  19.1 cells/mm
2, respectively; P 

0.05 (Fig. 9A–N). This suggests that SIS3 not only
inhibited EndoMT but also reduced the accumulation of
renal interstitial myoﬁbroblasts.
Effects of SIS3 on the early development of renal
ﬁbrosis, macrophage inﬁltration, and renal function.
Confocal microscopy and real-time PCR demonstrated
that compared with vehicle treatment, SIS3 signiﬁcantly
reduced collagen IV (Fig. 10A–C, G, and H) and ﬁbronectin
(Fig. 10D–F, G, and H) expression in the glomeruli and
tubulointerstitium of STZ-injected Tie2-Cre;Loxp-EGFP
mice. This suggests that SIS3 retarded the early develop-
ment of STZ-induced diabetic glomerulosclerosis and tu-
bulointerstitial ﬁbrosis. The renoprotective role of SIS3
was further conﬁrmed by serum creatinine levels (STZ
diabetic nephropathy plus SIS3 vs. STZ diabetic nephrop-
athy plus vehicle 0.088  0.013 vs. 0.11  0.014 mg/dl; P 

0.05.) (Fig. 10I). However, SIS3 administration did not
reduce proteinuria (urine albumin-to-creatinine ratio
221  100 vs. 180  78 g/mg for STZ diabetic nephropa-
thy plus SIS3 vs. STZ diabetic nephropathy plus vehicle,
respectively; P  0.05.) (Fig. 10J).
DISCUSSION
The present study showed that AGEs can induce EndoMT
in vitro and in vivo and also demonstrated the central role
of the RAGE-Smad3 signaling pathway in AGE-induced
EndoMT. More importantly, the present study demon-
strated the efﬁcacy of SIS3 in the inhibition of EndoMT in
vitro and in vivo and the renoprotective effects of SIS3 in
STZ-induced diabetic nephropathy. Taken together, these
ﬁndings suggest that EndoMT is a novel pathway leading
to the development and progression of diabetic nephrop-
athy and that SIS3 has therapeutic potential for diabetic
renal disease.
Zeisberg et al. (9) and Li et al. (10) have recently
demonstrated that EndoMT mediates the pathogenesis of
diabetic renal ﬁbrosis. In addition to TGF-1 and TGF-2,
the present study further identiﬁed AGEs as inducers of
EndoMT. Given the increasing evidence demonstrating a
causal role for AGEs in the development of diabetes
complications, AGE-induced EndoMT may also be an
important mechanism in the pathogenesis of diabetic
retinopathy and vasculopathy. Thus, blockade of AGE-
induced EndoMT may have therapeutic beneﬁt in retard-
ing the progression of diabetes complications.
The interaction between AGEs and RAGE on endothe-
lial cells initiates the activation of intracellular signaling
pathways (15–23). AGEs also activate Smad2/3 signaling
pathways through RAGE-MAPK cross-talk in nonendothe-
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FIG. 8. SIS3 inhibited AGE-induced EndoMT in Tie2-Cre;Loxp-
EGFP mice. Confocal microscopy demonstrated EGFP (green),
-SMA (red), and DAPI (blue) staining in MSA-treated (A), AGEs
plus vehicle–treated (B–F), and AGEs plus SIS3–treated (G)
mouse kidneys. Arrows indicate EGFP
/-SMA
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Original magniﬁcation: A, B, G, 600; C–F, 1,200. Quantiﬁcation
of percentage of -SMA
/EGFP
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 cells in
MSA-treated, AGEs plus vehicle–treated, and AGEs plus SIS3–
treated mouse kidneys (H). a, vs. MSA-treated group, P < 0.05; b,
vs. AGES plus vehicle–treated group, P < 0.05. (A high-quality
digital representation of this ﬁgure is available in the online
issue.)
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can induce Smad3 activation in endothelial cells and that
this Smad3 activation occurs largely through RAGE.
Blockade of AGE-RAGE engagement or Smad3 activation
inhibited AGE-induced EndoMT, indicating the essential
role of RAGE-Smad3 cross-talk in AGE-induced EndoMT.
Accordingly, RAGE-Smad3 cross-talk may be a therapeutic
target for diabetic nephropathy.
SIS3 has been shown to inhibit Smad3 phosphorylation
and abrogate TGF-1–induced ECM production in ﬁbro-
blasts (28). The present study demonstrated that SIS3 not
only inhibited AGE-induced Smad3 activation and En-
doMT in vitro but also abrogated Smad3 activation, de-
creased EndoMT, and retarded the progression of diabetic
nephropathy in vivo. Again, these ﬁndings suggest that
blockade of Smad3 phosphorylation may have therapeutic
potential for diabetic nephropathy, although further stud-
ies are obviously required.
In addition to AGEs, other proﬁbrotic mediators, such
as TGF- and connective tissue growth factor, are ele-
vated by AGEs in renal cells and can activate Smad3.
Smad3 is activated in a variety of renal cells besides
endothelial cells, such as tubular epithelial cells, ﬁbro-
blasts, and mesangial cells, which also contribute to renal
ﬁbrosis. SIS3 inhibits Smad3 activation in these renal cells.
Therefore, the effect of SIS3 in the kidney is not only
restricted to endothelial cells.
Clinical trials of RAS inhibitors in patients with both
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FIG. 10. SIS3 reduces renal ﬁbrosis in diabetic nephropathy. Confocal microscopy demonstrated collagen IV (A–C) and ﬁbronectin (D–F)
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kidneys. a, vs. normal saline, P < 0.05; b, vs. STZ-diabetic nephropathy plus vehicle, P < 0.05. H: Real-time PCR demonstrated -SMA, collagen
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plus SIS3 mouse kidneys. c, vs. NS, P < 0.05; d, vs. STZ-induced diabetic nephropathy plus vehicle, P < 0.05. I: Serum creatinine in normal saline,
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vehicle, and STZ-induced diabetic nephropathy plus SIS3 groups. No signiﬁcant differences were identiﬁed.
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on reducing renal and cardiovascular damage in patients
with advanced diabetic nephropathy with proteinuria
(30,31). However, large randomized clinical trials have
revealed that inhibition of the RAS fails to prevent the
development of early diabetic renal disease (5,32), sug-
gesting that additional mechanism(s) may participate in
the development of diabetic renal disease. The present
ﬁndings demonstrated that AGEs induced EndoMT in vitro
and in vivo and that blockade of Smad3 phosphorylation
by SIS3 signiﬁcantly reduced EndoMT, decreased glomer-
ulosclerosis and tubulointerstitial ﬁbrosis, and improved
renal function. These ﬁndings suggest that EndoMT is a
novel pathway leading to diabetic nephropathy and that
SIS3 may constitute a new measure to treat patients with
diabetic nephropathy.
Previous studies of Smad3 conditional knockout mice
with STZ-induced diabetes (25,26) or renal pathology due
to UUO (27) have demonstrated the essential role of
Smad3 in both glomerulosclerosis and tubulointerstitial
ﬁbrosis. However, the role of Smad3 in proteinuria re-
mains controversial. Fujimoto et al. (25) showed that
compared with wild-type mice, proteinuria was signiﬁ-
cantly decreased in Smad3 knockout mice with STZ-
induced diabetic nephropathy, while Wang et al. (26)
demonstrated that Smad3 deﬁciency limited diabetic glo-
merulosclerosis without affecting albuminuria. We have
previously reported that EndoMT occurs and contributes
to early renal interstitial ﬁbrosis independently of mi-
croalbuminuria (10). In the present study, SIS3 treatment
did not attenuate albuminuria. However, all of the above
studies investigated proteinuria in the early stages of
experimental diabetic kidney disease. The effect of SIS3 on
proteinuria in advanced diabetic nephropathy deserves
investigation.
In the present study, the anti-RAGE neutralizing anti-
body and RAGE siRNA signiﬁcantly inhibited AGE-in-
duced EndoMT in both MMECs and mouse renal
endothelial cells. Further, SIS3 almost completely blocked
AGE-induced EndoMT in MMECs and in Tie2-Cre;Loxp-
EGFP mouse kidneys. This suggests that RAGE is a major
receptor involved in the induction of EndoMT while
Smad3 plays an essential role in AGE-induced EndoMT.
The administration of SIS3 to mice with STZ-induced
diabetic nephropathy signiﬁcantly reduced, but did not
completely retard, the development of diabetic renal ﬁbro-
sis, suggesting that other pathological factors, such as
activation of p38MAPK (33,34), ERK (35,36), and protein
kinase C (37,38); high glucose (39,40); and oxidative stress
(41,42) may also be involved in the pathogenesis of
diabetic nephropathy.
In conclusion, the present study identiﬁed a novel
mechanism in which AGE-induced EndoMT occurs and
contributes to the development of diabetic renal ﬁbrosis.
RAGE-Smad3 cross-talk plays a central role in AGE-
induced EndoMT. SIS3 not only inhibits EndoMT but also
prevents structural damage and provides renal functional
protection. Blockade of EndoMT and RAGE-Smad3 cross-
talk may provide a new strategy to retard the progression
of diabetic nephropathy and other diabetes complications.
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